中國醫藥(600056.SH):天方有限瑞舒伐他汀鈣片獲得藥品註冊證書
格隆匯4月1日丨中國醫藥(600056.SH)公佈,近日,中國醫藥健康產業股份有限公司下屬全資子公司天方藥業有限公司(簡稱“天方有限”)收到國家藥品監督管理局核准簽發的兩份瑞舒伐他汀鈣片(簡稱“該藥品”)《藥品註冊證書》。
截至公吿披露日,天方有限在該藥品原料藥及片劑項目的累計研發投入約為1632萬元(未經審計),該藥品原料藥已通過國家藥品監督管理局藥品審評中心的技術審評。
該品適用於經飲食控制和其它非藥物治療(如:運動治療,減輕體重)仍不能適當控制血脂異常的原發性高膽固醇血癥(Ⅱa型,包括雜合子家族性高膽固醇血癥)或混合型血脂異常症(Ⅱb型);該品也適用於純合子家族性高膽固醇血癥的患者,作為飲食控制和其它降脂措施(如LDL去除療法)的輔助治療,或在這些方法不適用時使用。
根據第三方數據庫PDB查詢顯示,2021年該藥品國內樣本醫院銷售額約為3.77億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.